Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 92, Issue 2, 1998, Pages 201-206

  Sabchareon, A ^a   Attanath, P ^a   Phanuaksook, P ^a   Chanthavanich, P ^a   Poonpanich, Y ^b   Mookmanee, D ^b   Chongsuphajaisiddhi, T ^a   Sadler, B M ^c   Hussein, Z ^d   Canfield, C J ^e   Hutchinson, D B A ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Thongphaphum Hospital   (Thailand)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Pharmaceutical System Inc   (United States)

Author keywords

Atovaquone; Chemotherapy; Children; Malaria; Multidrug resistance; Pharmacokinetics; Plasmodium falciparum; Proguanil; Thailand

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CYCLOGUANIL; DRUG METABOLITE; PROGUANIL;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SCHOOL CHILD; THAILAND;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 13144275246     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(98)90749-0     Document Type: Article

References (28)

1. Almeida-Filho, H. & Souza, J. M. A. (1983). A simple urine test for sulfonamides. Bulletin of the World Health Organization, 61, 167-168.
2. Anabwani, G. & Esamai, F. (1996). Comparative clinical trial of a combination of atovaquone and proguanil versus halofantrine in the treatment of malaria in children in Kenya. In: The Role of Malarone™ in Antimalarial Chemotherapy, XIVth International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, 17-22 November 1996. Beckenham, UK etc.: Glaxo Wellcome. [Abstract.]
3. Basco, L. K., Ramiliarisoa, O. & Le Bras, J. (1995). In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 54, 388-391.
4. Canfield, C. J., Pudney, M. & Gutteridge, W. E. (1995). Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Experimental Parasitology, 80, 373-381.
5. Chongsuphajaisiddhi, T., Sabchareon, A. & Attanath, P. (1983). Treatment of quinine resistant falciparum malaria in Thai children. Southeast Asian Journal of Tropical Medicine and Public Health, 43, 357-362.
6. Davies, C. S., Pudney, M., Nicholas, J. C. & Sinden, R. E. (1993).The novel hydroxynaphthoquinine 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology, 106, 1-6.
7. De Alencar, F. E. C., Cerutti, C., jr, Durlacher, R. R., Boulos, M., Alves, F. P., Milhous, W. & Pang, L. W. (1997). Atovaquone and proguanil for the treatment of malaria in Brazil. Journal of Infectious Diseases, 175, 1544-1547.
8. Edstein, M. D., Shanks, G. D., Teja-isavadharm, P., Rieckmann, K. H. & Webster, H. K. (1994). Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. British Journal of Clinical Pharmacology, 37, 67-70.
9. Fry, M. & Pudney, M. (1992). Site of action of the antimalarial hydroxynaphthoquinone 2-[trans-4-(4'-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochemical Pharmacology, 43, 1545-1553.
10. Gibaldi, M. (1984). Biopharmaceutics and Clinical Pharmacokinetics, 2nd edition. Philadelphia: Lea & Febiger.
11. Gutteridge, W. E. (1996). Modes of action of atovaquone and proguanil and biochemical basis for their interaction. In: The Role of Malarone™ in Antimalarial Chemotherapy, XIVth International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, 17-22 November 1996. Beckenham, UK etc.: Glaxo Wellcome. [Abstract.]
12. Helsby, N. A., Edwards, G., Breckenridge, A. M. & Ward, S. A. (1993). The multiple dose pharmacokinetics of proguanil. British Journal of Clinical Pharmacology, 35, 653-656.
13. Hudson, A. T., Dickins, M., Ginger, C. D., Gutteridge, W. E., Holdich, T., Hutchinson, D. B. A., Pudney, A. M., Randall, A. W. & Latter, V. S. (1991). 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs under Experimental and Clinical Research, 17, 427-435.
14. Jones, A. E., Jardine, D. & Doig, M. V. (1991). An analytical method for the quantification of 566C80 in plasma using liquid-liquid extraction and reversed phase high performance liquid chromatography with ultraviolet delection. Beckenham, UK: Wellcome Foundation, mimeographed document BDCA/ 91/004.
15. Lelijveld, J. & Kortmann, H. (1970). The eosin colour test of Dill and Glazko: a simple field test to detect chloroquine in urine. Bulletin of the World Health Organization, 42, 477-479.
16. Looareesuwan, S., Viravan, C., Webster, H. K., Kyle, D. E., Hutchinson, D. B. & Canfield, C. J. (1996). Clinical studies of atovaquone, alone or in combination with other antimalarial drugs for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 54, 62-66.
17. Nosten, E., ter Kuile, F., Chongsuphajaisiddhi, T, Luxemburger, C.,Webster, H. K., Edstein, M., Phaipun, L., Kyaw Lay Thew & White, N. J. (1991). Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet, 337, 1140-1143.
18. Price, R. N., Nosten, F., Luxemburger, C., Kham, A., Brockman, A., Chonsuphajaisiddhi, T. & White, N. J. (1995). Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 523-527.
19. Radloff, P. D., Philipps, J., Nkeyi, M., Hutchinson, D. & Kremsner, P. G. (1996). Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet, 347, 1511-1514.
20. Roland, P. E. & Tanner, T. (1994). A comparison of bioavailability of three batches of 566C80. Beckenham, UK: Wellcome Foundation, mimeographed document BLVS/92/09.
21. Shanks, D., Andersen, S., Oloo, A., Gordon, D., Klotz, F., Aleman, G., Sadie, D. & Scott,T. (1996). The first field trial to determine the efficacy and safety of Malarone™ (atovaquone/proguanil) as a suppressive prolphylactic agent against Plasmodium falciparum malaria. In: The Role of Malarone™1 in Antimalarial Chemotherapy, XIVth International Congress for Tropical Medicince and Malaria, Nagasaki, Japan, 17-22 November 1996. Beckenham, UK etc.: Glaxo Wellcome. [Abstract.]
22. Sharp, J. P. & FookSheung, C. (1994). Validation of an analytical method for the determination of proguanil and cycloguanil in human plasma by HPLC with UV detection. Beckenham, UK: Wellcome Foundation, mimeographed document BDCR/ 94/0036.
23. Warrell, D. A., Molyneux, M. E. & Beales, P. F. (1990). Severe and complicated malaria, 2nd edition. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, supplement 2.
24. Watkins, W. M., Mberu, E. K., Nevill, C. G., Ward, S. A. Breckenridge, A. M. & Koech, D. K. (1990). Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84, 492-495.
25. Wattanagoon, Y., Taylor, R. B., Moody, R. R., Ochekpe, N. A., Looareesuwan, S. & White, N. J. (1987). Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. British Journal of Clinical Pharmacology, 24, 775-780.
26. Weller, S., Long, L., Kanics, L. L. & Blum, M. R. (1992). Interim analysis of S66C80 pharmacokinetics in patients with HIV infection and a history of Pneumocystis carinii. Beckenham, UK: Wellcome Foundation, mimeographed document TBZZ/92/0001.
27. White, N. J. (1992). Antimalarial drug resistance: the pace quickens. Journal of Antimicrobial Chemotherapy, 30, 571-585.
28. WHO (1973). Advances in Malaria Chemotherapy. Geneva: World Health Organization, Technical Report Series, no. 529, pp. 30-35.